Last reviewed · How we verify
F573 for injection
F573 for injection is a monoclonal antibody targeting the PD-1 receptor.
F573 for injection is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | F573 for injection |
|---|---|
| Sponsor | Beijing Continent Pharmaceutical Co, Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, F573 for injection blocks the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- F573 for Injection for the Treatment of Liver Injury/Failure (PHASE2)
- F573 Ia Clinical Trial (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F573 for injection CI brief — competitive landscape report
- F573 for injection updates RSS · CI watch RSS
- Beijing Continent Pharmaceutical Co, Ltd. portfolio CI